InMed Pharmaceuticals Inc. stocks have been trading up by 162.96 percent amid heightened optimism over its cannabinoid-based drug pipeline.
Live Update At 09:18:07 EDT: On Tuesday, May 19, 2026 InMed Pharmaceuticals Inc. stock [NASDAQ: INM] is trending up by 162.96%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.
Quick Financial Overview
INM is a classic early-stage biotech story on the numbers. Revenue for InMed Pharmaceuticals Inc. is only about $4.94M annually, while the latest quarterly report shows just $820,188 in operating revenue. Against that, INM is spending heavily: total quarterly expenses sit near $2.94M, driving an operating loss of roughly $2.12M and a net loss of about $2.03M. That lines up with brutal margins, with INM showing an EBITDA margin around -160% and profit margin near -170%.
For traders, the balance sheet is the bright spot. InMed Pharmaceuticals Inc. reports cash of about $6.95M and total assets of $11.19M, with total liabilities only $1.60M. Current ratio near 5.9 and quick ratio near 4.9 mean INM can cover near-term bills comfortably. The company’s book value per share is about $3.42, while the stock trades at a large discount to that, with a price-to-book near 0.19 and price-to-sales near 0.4.
Those deep discounts signal how little the market currently pays for INM’s pipeline and platform, but they also reflect the heavy, ongoing losses.
Why Traders Are Watching INM Price Action
The chart tells the real story for traders. On the daily timeframe, INM has been grinding lower. In late April, InMed Pharmaceuticals Inc. was closing around $0.77–$0.78, then slid into the low- to mid-$0.70s, and more recently into the $0.63–$0.68 zone. Each bounce has been sold, with lower highs forming from $0.81 to the mid-$0.70s and now down toward $0.70. That downtrend signals sellers still in control on the swing timeframe.
At the same time, INM intraday action shows why active traders keep this ticker on watch. One 5‑minute sequence has the stock opening near $1.30, spiking above $2.05, and then chopping between $1.80 and $1.90. That kind of range — more than 50% from low to high — is exactly what momentum and breakout traders look for. It shows INM can rip when volume pours in.
Under the hood, the fundamentals explain the caution. InMed Pharmaceuticals Inc. posts return on equity near -97% and return on assets around -77%. Free cash flow for the quarter is roughly -$2.38M, meaning INM is burning cash at a steady pace even with just 13 employees. While the enterprise value is negative, and valuation ratios look dirt cheap, traders understand that’s often a warning sign in small-cap biotech rather than a bargain by itself.
So the setup is simple: INM is a low‑priced, volatile stock with a decent cash runway but serious losses. That combination creates sharp moves both ways, rewarding traders who respect the trend and punish those who chase blindly.
More Breaking News
- AIIO Stock Rockets On Heavy Volume As Traders Hunt Volatility
- Keel Infrastructure Stock Drops After Wider Q1 Loss
- MU Stock Swings As Global Weakness Pressures Semis
- RIG Stock Climbs As Backlog Surges And Big Money Steps In
Conclusion
For active traders, INM sits in that dangerous but tradable zone where volatility, dilution risk, and deep losses all collide. InMed Pharmaceuticals Inc. shows a strong working-capital position, with roughly $7.31M in working capital and very light debt, so the lights stay on for now. But the income statement remains ugly, with recurring losses, negative cash flow, and efficiency metrics that scream “early-stage biotech still searching for scale.”
That’s why the market is assigning INM a low valuation, despite book value per share far above the current quote. Traders know that cheap can always get cheaper when a company is burning cash. At the same time, they also know thin, low-float names like InMed Pharmaceuticals Inc. can produce monster percentage moves on any spike in volume or positive headline.
The game plan many in the Tim Sykes-style community would favor is clear: treat INM as a trading vehicle, not a long-term home. Wait for clear patterns, confirm with volume, and cut losers fast. As millionaire penny stock trader and teacher Tim Sykes, says, “It’s not about how much money you make; it’s about how much money you keep.” As Tim Sykes loves to remind traders, “The stock market doesn’t care about your opinion, only your preparation.” With INM, that preparation means understanding the brutal financials, respecting the trend, and only attacking the best, most liquid setups.
This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.
Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:
- Penny Stocks Trading Guide
- Best Penny Stocks Under $1 to Buy Today
- Top 8 Penny Stocks to Watch on Robinhood
Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:
Leave a reply